MEDI7510 is composed of MedImmune’s RSV sF antigen plus GLA, a synthetic molecule licensed from Immune Design’s GLAAS discovery platform. This follows an existing agreement between the two
Tekmira is also conducting a separate Phase I/II clinical trial evaluating TKM-PLK1 in patients with Gastrointestinal Neuroendocrine Tumors (GI-NET) or Adrenocortical Carcinoma (ACC). "Hepatocellular carcinoma is associated with
The IND was filed by SCI with support from Stemedica Asia, a subsidiary of Stemedica, and was based on Stemedica’s United States FDA-approved Phase II AMI trial protocol.
The patent claims a novel form of rugged dsRNA. Rugged dsRNA are nucleic acids with a unique composition and physical characteristic identified with high specificity of binding to
Solara Labs Founder & CEO, Dr. J. Rocca, remarked, "I am thrilled to bring our great-tasting, all-natural melts to the Bariatric community. The BariMelts brand represents our finest
TECFIDERA is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA is indicated as monotherapy for the treatment of RRMS to reduce the frequency of
Probodies are monoclonal antibodies that are selectively activated within the cancer microenvironment, focusing the activity of therapeutic antibodies to tumors and sparing healthy tissue. The unique selectivity of
The notice of allowance for US Patent Application No. 13/258,808 entitled Depot Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof, also awarded additional claims to an earlier patent
These laboratories do significant government work and have expertise in anti-infective, anti-fungal and bio-defense applications. Cellceutix will be shipping the compounds to the university laboratories in the coming
BioInvent has successfully manufactured ADC-1013 (a FIND optimized n-CoDeR antibody) and will fulfill the remaining CMC activities required to supply drug product to the First-in-Human study, expected to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.